Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial
M van der Heiden, S Shetty, E Bijvank… - Nature …, 2024 - nature.com
Vaccine responsiveness is often reduced in older adults. Yet, our lack of understanding of
low vaccine responsiveness hampers the development of effective vaccination strategies to
reduce the impact of infectious diseases in the ageing population. Young-adult (25–49 y),
middle-aged (50-64 y) and older-adult (≥ 65 y) participants of the VITAL clinical trials (n=
315, age-range: 28-98 y), were vaccinated with an annual (2019–2020) quadrivalent
influenza (QIV) booster vaccine, followed by a primary 13-valent pneumococcal-conjugate …
low vaccine responsiveness hampers the development of effective vaccination strategies to
reduce the impact of infectious diseases in the ageing population. Young-adult (25–49 y),
middle-aged (50-64 y) and older-adult (≥ 65 y) participants of the VITAL clinical trials (n=
315, age-range: 28-98 y), were vaccinated with an annual (2019–2020) quadrivalent
influenza (QIV) booster vaccine, followed by a primary 13-valent pneumococcal-conjugate …
Multiple vaccine comparison in the same adults from the VITAL study reveals vaccine-specific and age-related humoral response patterns
M Van Der Heiden, S Shetty, E Bijvank, L Beckers… - medRxiv, 2024 - medrxiv.org
Vaccine responsiveness is often reduced in older adults. Yet, our lack of understanding of
low vaccine responsiveness hampers the development of effective vaccination strategies to
reduce the impact of infectious diseases in the ageing population. Young-adult, middle-aged
and older-adult participants of the VITAL clinical trials (n= 315, age range: 28-98y), were
consecutively vaccinated with a booster quadrivalent influenza (QIV) vaccine, a primary 13-
valent pneumococcal-conjugate (PCV13) vaccine, and a primary series of SARS-CoV2 …
low vaccine responsiveness hampers the development of effective vaccination strategies to
reduce the impact of infectious diseases in the ageing population. Young-adult, middle-aged
and older-adult participants of the VITAL clinical trials (n= 315, age range: 28-98y), were
consecutively vaccinated with a booster quadrivalent influenza (QIV) vaccine, a primary 13-
valent pneumococcal-conjugate (PCV13) vaccine, and a primary series of SARS-CoV2 …
